Vol 24, No 2 (2017)
Letters to the Editor — Clinical cardiology
Published online: 2017-04-14

open access

Page views 1459
Article views/downloads 1480
Get Citation

Connect on Social Media

Connect on Social Media

Determinants of improvement in six-minute walk distance from admission to discharge in acute systolic heart failure: Analysis from the ESCAPE trial

Hesham R. Omar, Maya Guglin
Pubmed: 28421593
Cardiol J 2017;24(2):227-230.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Fleg JL, Pina IL, Balady GJ, et al. Assessment of Functional Capacity in Clinical and Research Applications : An Advisory From the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000; 102(13): 1591–1597.
  2. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1): 111–117.
  3. Passantino A, Lagioia R, Mastropasqua F, et al. Short-term change in distance walked in 6 min is an indicator of outcome in patients with chronic heart failure in clinical practice. J Am Coll Cardiol. 2006; 48(1): 99–105.
  4. Abraham WT, Fisher WG, Smith AL, et al. MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002; 346(24): 1845–1853.
  5. Binanay C, Califf RM, Hasselblad V, et al. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005; 294(13): 1625–1633.
  6. Shah MR, Hasselblad V, Stinnett SS, et al. Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. J Card Fail. 2001; 7(2): 105–113.
  7. Gualeni A, D'Aloia A, Gentilini A, et al. Effects of maximally tolerated oral therapy on the six-minute walking test in patients with chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1998; 81(11): 1370–1372.
  8. Hutcheon SD, Gillespie ND, Crombie IK, et al. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart. 2002; 88(4): 373–377.
  9. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995; 92(6): 1499–1506.
  10. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996; 94(11): 2793–2799.